TARSUS PHARMACEUTICALS, INC. — Revenue by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/90af1b0e-07ef-4f75-b21e-2ba8fdf96481/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $451.4M | 2025-01-01 – 2025-12-31 | evidence 0001819790-26-000019 |
| FY 2024 | $183.0M | 2024-01-01 – 2024-12-31 | evidence 0001819790-25-000011 |
| FY 2023 | $17.4M | 2023-01-01 – 2023-12-31 | evidence 0001819790-24-000018 |
| FY 2022 | $25.8M | 2022-01-01 – 2022-12-31 | evidence 0001819790-23-000007 |
| FY 2021 | $57.0M | 2021-01-01 – 2021-12-31 | evidence 0001819790-22-000010 |
| FY 2020 | $0 | 2020-01-01 – 2020-12-31 | evidence 0001819790-22-000010 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
TARSUS PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income